Skip to content
Disclosery

Athyrium Capital Management, LP

Follow

13F filer, CIK 1728001, New York, NY

Athyrium Capital Management, LP reported $8,686,216 across 2 holdings for the quarter ended 2024-09-30, in a 13F-HR filed 2024-11-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-24-000336

Period
2024-09-30
Reported value
$8.69M
Holdings
2
Top 10 weight
100%
New
0
Sold out
1

Holdings, Q3 2024

Share positions as resolved from 13F-HR 0001123292-24-000336, largest first. % of portfolio is the value over $8,686,216, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: not reported; 2023Q1: 1,694,481 shares; 2023Q2: 1,694,481 shares; 2023Q3: 10,929,762 shares; 2023Q4: 10,929,762 shares; 2024Q1: 10,929,762 shares; 2024Q2: 10,929,762 shares; 2024Q3: 10,929,762 shares 10,929,762$5.48M63.12%0
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: 1,792,114 shares; 2023Q1: 1,792,114 shares; 2023Q2: 1,792,114 shares; 2023Q3: 1,792,114 shares; 2023Q4: 1,792,114 shares; 2024Q1: 1,256,411 shares; 2024Q2: 1,256,411 shares; 2024Q3: 1,256,411 shares 1,256,411$3.2M36.88%0Timeline

Sold out in Q3 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
COHERUS ONCOLOGY INCCOHERUS ONCOLOGY INC30,000,000$22.2Mprincipal

How Q3 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-24-000336 base2024-11-12acceptance time not in the bulk data set